Navigation Links
Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
Date:12/4/2009

NEW YORK, Dec. 4 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The poster will be presented by Stemline's collaborators at The University of Texas M.D. Anderson Cancer Center.

The data demonstrate in vitro and in vivo activity of both SL-401 and SL-501 against CML and CML cancer stem cells as single agents, and in combination with tyrosine kinase inhibitors (TKIs). Results also include activity of these IL-3R targeting agents against CML cells with mutations that render them resistant to TKIs.

Details on the abstract selected for presentation are as follows:


Abstract #:          2172

TITLE:               Targeting IL-3 Receptor in Chronic Myeloid Leukemia

Lead Author          Olga Frolova, MD, PhD

Session Name         Chronic Myeloid Leukemia -Biology and Pathophysiology
                     excluding Therapy Poster I

Date                 Sunday, December 6, 2009

Presentation Time:   6:00PM - 8:00PM

Location:            Hall E (Ernest N. Morial Convention Center)

Poster Board no.:    II-149

A copy of the above referenced abstract can be viewed online through the ASH website (www.hematology.org).

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells.
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... WA (PRWEB) , ... August 03, 2015 , ... ... and TLD5000 diaphragm vacuum pumps to its comprehensive line of analytical laboratory equipment. ... steel valves, these versatile pumps provide a chemically resistant and maintenance-free solution for ...
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... Inc. (OTC Bulletin Board: GOVX ), a biotechnology ... announced the results of its Annual Shareholders Meeting, held on ... seven nominees for directors of the company to serve until ... are duly elected or appointed and qualified. They are: ...
... VPRIV(R) (velaglucerase alfa) for the Treatment of... -- CAMBRIDGE, Massachusetts, August 26, 2010 ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Aug. 26 CreAgri, Inc. ®  announced ... by the Australian Patent Office, Patent Number 2003249719, ... against skin damage caused by UV exposure. ... include formulations containing the two most important olive ...
Cached Biology Technology:GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations 2Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations 3
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... grow, a researcher at MIT's Picower Institute for Learning and ... of Science (PLoS) Biology that structural remodeling of neurons does ... means that it may one day be possible to grow ... cord injury, such as the one that paralyzed the late ...
... Max Planck researchers uncover how a nanoscale 'compass' inside ... The entire bacterium is oriented like a compass needle ... clear how the cells organise magnetosomes into a stable ... attraction. But using modern molecular-genetic and imaging processes, researchers ...
... Scientists from the National Institute of Allergy and ... of Health, have determined how a promising drug ... Published online this week in Proceedings of the ... scientists optimize the drug candidate, PA-824, which targets ...
Cached Biology News:MIT researcher finds neuron growth in adult brain 2MIT researcher finds neuron growth in adult brain 3Bacteria which sense the Earth's magnetic field 2Bacteria which sense the Earth's magnetic field 3Bacteria which sense the Earth's magnetic field 4NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3
ID clarifier: Without ethidium bromide...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
...
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
Biology Products: